Skip to main content
. 2020 Dec 19;9(12):1066. doi: 10.3390/pathogens9121066

Table 1.

Representative list of A. baumannii vaccine studies conducted over the past decade reported in NCBI.

Immunization Challenge
Vaccine Platform Antigens Adjuvant(s) Route Mouse Strain Strain Route Dose Survival Ref
Whole bacteria A. baumannii Δmurl1 or Δmurl2 - IP BALB/c ATCC 17978 IP 3 × 108 CFU 100% [73]
A. baumannii ΔtrxA - IP, SC C57BL/6 Clinical Isolate 79 (Ci79) IP 104–107 CFU IP—100%
SC—90%		 [74]
A. baumannii (Ali190) BGs Freund’s adjuvant Oral, SC, IM, IP, SCA, IMA Sprague-Dawley rats (male) Ali190 IP 108 CFU Oral—67%
SC, IM, IP, SCA, IMA—100%		 [76]
Formalin-killed A. baumannii LAC-4 cells (5 × 107 CFU) - IN WT, Igh-Jtm1Dhu, and Fcer1gtm1Rav BALB/c LAC 4 IN or IP 5 × 107 CFU IN challenge—100%
IP challenge—100%		 [122]
Outer membrane vesicles or complexes OMVs isolated from A. baumannii strain 19606 Alum SC C57BL/6 Ab112 IP 107 CFU OMV vaccine w/Levofloxacin—85%
OMV vaccine only—0%		 [77]
OMVs isolated from A. baumannii strain 19606 Alum IM C57BL/6 ATCC 19606, Ab-154, Ab-113-16 IP 4.5 × 105 19606 challenge—100%
Ab-154 challenge—90%
Ab-113-16—100%		 [90]
LPS-negative OMVs isolated from IB010 Alum IM C57BL/6 ATCC 19606 IP 1.8 × 106 CFU 70% [91]
OMCs isolated from A. baumannii strain IB010 (ΔlpxD) Alum IM C57BL/6 ATCC 19606 IP 1.6 × 106 60% [92]
SuOMVs, nOMVs, or sOMVs isolated from strain 17978 Alum IM and IN C57BL/6 LAC 4 IT 2 × 107 CFU IM—60–100%
IN—50–70%		 [93]
OMVs isolated from DH5α E.coli displaying A. baumannii Omp22 Alum SC ICR Ab1 IP 1.6 × 106 100% [123]
A. baumannii IB010 Alum IM C57BL/6 ATCC 19606 IP 108 CFU 100% [124]
OMVs isolated from A. baumannii strain Ab1 Alum IM ICR Ab1 IN or IP IN challenge—5 × 107
IP challenge—5.5 × 105 		IN challenge—100%
IP challenge—73%		 [125]
DNA-based vaccine DNA encoding A. baumannii OmpA gene Alum IM BALB/c MDR clinical A. baumannii strain IN 108 CFU 60% [94]
DNA encoding genes for A. baumannii OmpA and Pal CpG IM C57BL/6 LAC 4 IN or IT 3 × 107 CFU IN challenge—80%
IT Challenge—50%		 [95]
Purified or Recombinant Subunit rHis-Blp1(2652–3362) Freund’s Adjuvant IM BALB/c Ab1 IP 108 CFU 60% [99]
rHis-Bap Freund’s Adjuvant IM BALB/c Clinical isolate IP 108 CFU 80% [100]
rHis-Oma87 Freund’s Adjuvant SC BALB/c 19606 IP 2 × 106 CFU 100% [101]
rHis-OprF(25–200) BCG and Alum SC Swiss Albino 9027 IP 3.2 × 109 CFU 50% [102]
rHis-Omp22 Alum SC ICR 17978 IP 1.6 × 106 CFU 100% [103]
rHis-OmpA Alum SC Retired breeder or juvenile BALB/c HUMC1 IV 2 × 107 CFU Retired breeder—50%
Juvenile—45%		 [104]
rHis-OmpA Cholera toxin IN BALB/c 19606 IP 5 × 108 CFU 50% [106]
rHis-PKF with anti- A. baumannii OmpA antibodies Alum IP C57BL/6 19606 IP 108 CFU 85.71% [107]
rHis-FilF Freund’s Incomplete Adjuvant SC BALB/c 19606 IT 108 CFU 50% [108]
rHis-BamA Alum SC BALB/c 19606 IN 109 CFU 70% [113]
rHis-NucAb Freund’s complete adjuvant IP BALB/c 19606 IT 108 CFU 20% [114]
rHis-SmpA/PLD Alum SC BALB/c ST191 IT 108 CFU 66.7% [115]
rHis-CsuA/B and rHis-FimA Freund’s Complete Adjuvant SC BALB/c 19606 IP 2 × 108 CFU Csu-Fim—60%
Fim—50%
Csu—33.3%		 [117]
rHis-ZnuD (loop 2, 5, 7, or 11) attached to TbpA scaffold Freund’s Complete Adjuvant SC BALB/c 19606 IP 107 CFU Loop 2—40%
Loop 5—30%
Loop 7—50%
Loop 11—35%
Loop 2,5,7,11—100%		 [118]
rHyr1p-N (Candida albicans) Alum SC BALB/c HUMC1 Aerosol 5 × 107 CFU 50% [121]
rHis-OmpK/Omp22 MF59 IT BALB/c 19606 IT 108 CFU 83.3% [126]
rHis-OmpK/Omp22 Freund’s complete adjuvant SC BALB/c Ab1 IP 2 x 108 CFU 66.7% [127]
rHis-OmpW Alum SC ICR Ab1 IP 106 CFU 100% [128]

BGs = Bacterial ghost. SC = subcutaneous. SCA = subcutaneous with adjuvant. IMA = intramuscular with adjuvant. IT = Intratracheal. IP = Intraperitoneal. IM = Intramuscular. IN = Intranasal. IV—Intravenous. Aerosol = Aerosolization.